Numais Overview

  • Year Founded
  • 2019

Year Founded

  • Status
  • Out of Business

  • Employees
  • 3

Employees

  • Latest Deal Type
  • Out of Business

Numais General Information

Description

Developer of a diagnostic treatment intended for vascular stenosis and atherosclerosis. The company uses state-of-the-art synthesis methodologies on the stem-cell-derived nanovesicle theranostics and the thermo-sensitive biodegradable hydrogel delivery systems to maximize the efficacy of the stem-cell therapeutics and the predictability of drug delivery systems, enabling patients to improve the grade of life for those suffering from various types of inflammatory diseases.

Contact Information

Website
www.numais.com
Ownership Status
Out of Business
Financing Status
Formerly VC-backed
Corporate Office
  • 2nd Floor, Room Numbers 201, 202, 203, SKV E1 Center 2
  • 31 Gwangnaru-ro 8-gil, Seongdong-gu
  • Seoul
  • South Korea
+82
Primary Industry
Drug Delivery
Other Industries
Drug Discovery
Pharmaceuticals
Diagnostic Equipment
Corporate Office
  • 2nd Floor, Room Numbers 201, 202, 203, SKV E1 Center 2
  • 31 Gwangnaru-ro 8-gil, Seongdong-gu
  • Seoul
  • South Korea
+82

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Numais Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
3. Out of Business 23-Jan-2024 Completed Out of Business
2. Early Stage VC 07-May-2021 Completed Pre-Clinical Trials
1. Early Stage VC (Series A) 07-Jun-2020 $3.17M $3.17M Completed Startup
To view Numais’s complete valuation and funding history, request access »

Numais Patents

Numais Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2022245144-A1 Method for production of cell-derived nanovesicles by using high-pressure fluid dispersion Inactive 20-May-2021
WO-2022240243-A1 Skin-whitening composition containing nanovesicles Inactive 14-May-2021
JP-2022546423-A Diagnosis and treatment of arteriosclerosis using blood flow alteration site-targeting nanovesicles Pending 30-Aug-2019
EP-4024048-A1 Method for diagnosing and treating atherosclerosis by using nanovesicle targeting site of change in blood flow Inactive 30-Aug-2019
EP-4024048-A4 Method for diagnosing and treating atherosclerosis by using nanovesicle targeting site of change in blood flow Inactive 30-Aug-2019 G01N33/6893
To view Numais’s complete patent history, request access »

Numais Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Numais FAQs

  • When was Numais founded?

    Numais was founded in 2019.

  • Where is Numais headquartered?

    Numais is headquartered in Seoul, South Korea.

  • What is the size of Numais?

    Numais has 3 total employees.

  • What industry is Numais in?

    Numais’s primary industry is Drug Delivery.

  • Is Numais a private or public company?

    Numais is a Private company.

  • What is Numais’s current revenue?

    The current revenue for Numais is .

  • How much funding has Numais raised over time?

    Numais has raised $6.03M.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process